Within the depth-psychology and neuropsychiatric corpus, amphetamine occupies a dual position: it is simultaneously a first-line pharmacotherapeutic agent for attentional dysregulation and a pharmacological probe for mapping dopaminergic and monoaminergic systems in the living brain. Faraone’s comprehensive 2018 review anchors the dominant biomedical voice, situating amphetamine’s mechanism of action — principally the reversal of monoamine transporters and the consequent surge in extracellular dopamine, norepinephrine, and serotonin — within the neurobiology of ADHD and its comorbidities. Neuroimaging studies employing PET and SPECT consistently deploy amphetamine as a challenge agent, exploiting its capacity to displace D2 receptor ligands as an index of endogenous dopamine release. A secondary but significant strand concerns sex and the menstrual cycle: Justice and de Wit, and subsequently White, demonstrate that oestrogen potentiates amphetamine efficacy while progesterone attenuates it, introducing a hormonal dimension that complicates the assumption of uniform pharmacokinetics. Paulus contributes a third axis, implicating amphetamine dependence in insular hypoactivation and dysregulated interoception, thus linking chronic amphetamine exposure to relapse vulnerability. Blum’s reward-deficiency framework further contextualises amphetamine treatment within a broader genetic and dopaminergic deficit model. The tension between therapeutic utility and addiction risk runs as an unresolved undertow throughout the corpus.
The main mechanism of action of AMP is to increas[e] extracellular monoamine concentrations… A publication was excluded if it did not specifically focus on the mechanism of action or pharmacologic effects of AMP or MPH.
This passage establishes the pharmacological framework of the entire review, centring amphetamine’s mechanism on monoamine transporter reversal and delimiting the evidentiary scope to preclinical and healthy-subject neuroimaging studies.
AMP and MPH have been shown to exhibit comparable efficacy in 2 meta-analyses… with other analyses reporting that AMP has moderately greater effects than MPH.
Faraone positions amphetamine as marginally superior to methylphenidate in efficacy while noting comparable tolerability profiles, establishing the clinical rationale for its first-line status in ADHD treatment.
There was a positive correlation between the effectiveness of D-amphetamine and the oestrogen concentration: the greater the oestrogen concentration was, the greater the effectiveness of D-amphetamine.
Findeis synthesises findings demonstrating that oestrogen enhances and progesterone attenuates amphetamine efficacy across the menstrual cycle, revealing a hormonally modulated pharmacodynamic variability.
, The effects of psychostimulants in menstruating women with ADHD — A gender health gap in ADHD treatmentthesis
AMP-induced reductions in [11C]raclopride (a D2 receptor antagonist) binding in the anteroventral striatum of healthy adults, as measured by PET, were negatively correlated with feelings of euphoria.
This entry documents the inverse relationship between striatal dopamine displacement and subjective euphoria, linking amphetamine’s neurochemical signature directly to its hedonic effects.
, The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities, 2018supporting
AMP increased electrically evoked DA levels, inhibited DA uptake, and upregulated DA vesicular release in rat striatum.
Preclinical evidence summarised here confirms that amphetamine acts through multiple dopaminergic mechanisms simultaneously — stimulating release, inhibiting reuptake, and enhancing vesicular storage mobilisation.
, The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities, 2018supporting
AMP exhibited high affinity for DA, NE, and 5-HT reuptake sites and for α2 adrenergic receptor sites, as measured using in vivo binding in rats.
This summary of preclinical binding data establishes amphetamine’s broad monoaminergic and adrenergic receptor profile, underpinning its diverse central and peripheral effects.
, The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities, 2018supporting
AMP reduced [123I]IBZM and [123I]IBF (D2 receptor antagonists) in vervets (nonhuman primates), as measured by SPECT, with binding changes correlating with peak DA release as measured by microdialysis.
Cross-validating SPECT displacement with microdialysis, this passage confirms amphetamine-induced dopamine release as the operative mechanism underlying ligand binding changes observed in neuroimaging.
, The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities, 2018supporting
In amphetamine users, fMRI studies show attenuated insula activation in cognitive control and emotion processing tasks… attenuated insula activation during a simple decision-making task was associated with increased propensity for relapse.
Paulus implicates chronic amphetamine use in interoceptive dysregulation, specifically linking hypoactivation of the insula during decision-making to elevated relapse risk.
, Treatment approaches for interoceptive dysfunctions in drug addiction, 2013supporting
Both systolic blood pressure and ratings of ‘Feel drug’ were similar between the two phases suggesting that the variations in effects were specific to certain measures.
Justice’s methodological reflection clarifies that menstrual-phase differences in amphetamine response are measure-specific rather than attributable to gross pharmacokinetic variation.
, Acute effects of d-amphetamine during the follicular and luteal phases of the menstrual cycle in women, 1999supporting
ADHD may be the precursor for multiple addictions including alcohol, drugs, food, sex, and even gambling… there is an association between a severe form of alcoholism and defects in the D2 gene in the reward area of the brain.
Blum situates amphetamine treatment within a reward-deficiency syndrome framework, arguing that ADHD’s dopaminergic substrate predisposes individuals to broader addictive vulnerabilities.
, Attention-deficit-hyperactivity disorder and reward deficiency syndrome, 2008supporting
Reductions in ligand binding in PET [following amphetamine challenge are documented across multiple studies including] Boileau et al., 2007; Buckholtz et al., 2010; Cardenas et al., 2004.
This citation cluster documents the breadth of PET evidence for amphetamine-induced dopamine release across healthy and clinical populations, serving as a bibliographic anchor for the neuroimaging literature.
Amphetamine modulates brain signal variability and working memory in younger and older adults.
This reference extends amphetamine’s documented cognitive effects to age-related working memory modulation, broadening its relevance beyond ADHD populations.